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Introduction: The elevated risk of ischaemic heart disease in patients with rheumatoid arthritis (RA) has been
linked to inflammation and disease severity. Treatment with tumour necrosis factor inhibitors (TNFis) is often
effective in reducing disease activity and could possibly modify cardiovascular risk. Our objective in the study was
to evaluate the risk of acute coronary syndrome (ACS) in patients with RA treated with TNFis compared with the
risk among biologic-naïve RA patients and the general population.
Methods: By linkage of the Swedish National Patient Register and the Swedish Biologics Register, we identified a
cohort of patients who were started on their first biologic, a TNFi, between 2001 and 2010 (N = 7,704), and a cohort
comprising matched biologic-naïve RA patient referents at a 3:1 ratio. Furthermore, a matched comparator cohort
(5:1 ratio) was extracted from the Swedish population register. The incidence rates of a first ACS event were calculated
and compared between cohorts using Cox proportional hazards regression in three different risk windows:
‘ever-exposed’, ‘actively on TNFi’ and ‘short-term exposure’ (active treatment maximized to 2 years). The models
were adjusted for disease duration, joint surgery, comorbidity and socioeconomic factors, and, in a sensitivity
analysis including a subpopulation started on therapy beginning 1 January 2006 or later, for dispensed drugs.
Results: Based on 221 events in 7,704 patients (comprising 32,621 person-years) treated with TNFi biologics, the
hazard ratio ((HR); ever-exposed) for ACS among the TNFi-exposed RA patients compared with biologic-naïve RA
patients was 0.8 (95% confidence interval (CI) = 0.7 to 0.95). In comparison with the general population referents,
statistical analysis using fully adjusted models resulted in a HR of 2.0 (95% CI = 1.8 to 2.3) for biologic-naïve RA
patients and a HR of 1.6 (95% CI = 1.4 to 1.9) for the TNFi-exposed group. Similar risk estimates were obtained
using the other two risk windows. A sensitivity analysis in which we compared the TNFi-exposed patients included
from 1 January 2006 onward with biologic-naïve patients resulted in a HR (ever-exposed) of 0.7 (95% CI = 0.5 to 1.0).
Conclusions: RA patients treated with TNFi had a lower risk of ACS compared with biologic-naïve RA patients.
Compared with the general population, the risk among patients with RA was elevated, although the difference
was less pronounced among the TNFi-exposed patients. This finding could be attributable to the TNFi as such, or
it could correspond to a lower degree of inflammation in the TNFi-treated group.* Correspondence: lotta.ljung@vll.se
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Rheumatoid arthritis (RA) is associated with an in-
creased risk for cardiovascular disease (CVD) [1]. The
level of increased risk, approximately a doubled risk for
myocardial infarction compared with the general popula-
tion, is in parity with the risk in patients with diabetes
mellitus [2-6]. The relative contributions of traditional
risk factors to the CVD risk in RA is lower than that in
the general population, indicating the importance of fac-
tors related to the RA disease itself or to its treatment
[7-10]. Control of the systemic inflammation associated
with RA, together with identification and management
of traditional risk factors, might therefore prove to be an
effective measure to prevent myocardial infarctions in
patients with RA [11].
Investigators in several published observational studies
have examined the possible effect of disease-modifying an-
tirheumatic drugs (DMARDs) and/or biologic therapies
(mainly tumour necrosis factor inhibitors (TNFis)) on the
risk for ischaemic coronary events in RA [12-21]. A statis-
tically significant reduction in the risk for ischaemic heart
disease was observed by researchers in three studies
[12,14,16]. In the other studies [13,15,17-21], no associa-
tions between biologic therapy and the risk for ischaemic
heart disease were observed, leaving unanswered the im-
portant question whether TNFis may indeed improve not
just RA disease activity, but ultimately also the cardiovas-
cular comorbidity profile in RA.
In a previous study on the risk for acute coronary syn-
drome (ACS) after TNFi exposure in patients with early
RA (average RA disease duration of 1.4 years at the start
of TNFi therapy), we observed a 20% lower risk for ACS
among patients started on TNFi therapy compared to
patients treated otherwise (relative risk (hazard ratio
(HR)) = 0.80, 95% confidence interval (CI) = 0.52 to 1.24)
[15]. The lack of a significantly lower risk among the
TNFi-exposed patients might be due to lack of a true
protective effect or a lack of precision of the data, but it
also might be due to the difference in the average level
of accrued disease control (whether obtained through
TNFi or alternative therapies) being too small to allow
for a ‘protective’ effect of TNFi to be observed. Our
purpose in the present study was therefore to evaluate
the role of TNFi treatment on the risk for ACS in a




For this study, in which we employed a matched, pro-
spective, population-based cohort design, the study popu-
lations were identified from among the individuals in the
Swedish Biologics Register, the Swedish National Patient
Register and the Swedish population register (StatisticsSweden). The Swedish setting, including its population-
based registers, have previously been described elsewhere
[22-24].
In brief, Statistics Sweden holds data on immigration,
emigration, vital status and residency, as well as data on
socioeconomic factors such as civil status and education
level, for all residents in the country. The Swedish Na-
tional Patient Register is a population-based register with
information on inpatient care since 1964 and full coverage
since 1987. In addition, since 2001, outpatient visits to
both public and private caregivers other than in a primary
care setting have also been included in the register. The
register is updated annually. For this study, data through
31 December 2010 were available. The information in the
National Patient Register is divided into four groups: (1)
patient data such as the unique individual personal identi-
fication number and place of residence, (2) geographical
data such as hospital and department, (3) administrative
data such as visit dates or dates of admission and dis-
charge and (4) medical data such as main and secondary
diagnoses. The discharge diagnoses are coded by the dis-
charging physician according to the codes assigned by the
International Classification of Diseases (ICD), revisions 7
to 10. The Swedish Biologics Register has been in use
since 1998 for follow-up of patients with RA and other
rheumatologic conditions who are older than 18 years of
age and were started on a biologic treatment. All public
and private rheumatology clinics and practices report data
to be included in the register, with an estimated national
coverage of around 90% regarding prescribed TNFi drugs
(H Wadström, personal communication) [25]. Further-
more, we used data extracted from the Swedish Cause of
Death Register, which contains information on dates and
causes of death for all residents who have died since
1961, and the Prescribed Drug Register, which has in-
formation on prescribed drugs for ambulatory care dis-
pensed by Swedish pharmacies since July 2005.
Study population
Patients with two or more clinical visits or hospitaliza-
tions for which RA was listed as the main or contribu-
tory diagnosis in the National Patient Register, of which
at least one was recorded in the Outpatient Register
between 2001 and 2010 at an internal medicine or
rheumatology department, were defined as having RA.
ICD codes are listed in Additional file 1. This RA defin-
ition has previously been shown to result in an RA dis-
ease prevalence of approximately 0.6% [26]. Data were
extracted from the Swedish Biologics Register for pa-
tients older than 18 years of age who had RA according
to this definition, were started on treatment with a
first-ever biologic (a TNFi) between 1 January 2001 and
31 December 2010 and had no diagnosis of ischaemic
or congestive heart disease recorded in the National
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We hereinafter refer refer to these patients as index pa-
tients. For each index patient, we identified up to three
randomly assessed, matched referents with RA (accord-
ing to our definition above) who were alive and unex-
posed to TNFi at the time point for the start of TNFi
for the index patient and who did not have a previous
diagnosis of ischaemic or congestive heart disease. The
matching date we assigned to these matched but
biologic-naïve referent patients was the date of start of
TNFi treatment of their index patient. The matching
was performed in four steps (with each referent being
assigned to only one index patient). (1) We used a 1:2
matching algorithm based on sex, age in 5-year strata
and county of residence. (2) For any index patient not
assigned two referents in step 1, we matched on sex,
age in 10-year strata and county of residence. (3) For
index patients still without two referents, we matched by
sex and by age in 10-year strata. (4) We repeated steps 1
to 3 to find a third referent for each index patient. In total,
23,112 RA referents (the biologic-naïve RA cohort) were
identified. From among the individuals in the Swedish
population register, we identified five general population
referents without any previous diagnosis of ischaemic or
congestive heart disease, who were randomly assigned and
matched for sex, age in 5-year strata and county of resi-
dence to each index patient (N = 38,520).
The Regional Ethical Review Board in Stockholm ap-
proved the study and waived the requirement for indi-
vidual consent for this register-based study.
Follow-up
The follow-up for each individual started at the matching
date and ended at death, emigration, 31 December 2010,
the time point for first ACS event or (for the biologic-
naïve referents) at the reported start date for any biologic
agent, whichever came first. Three different risk windows
were defined as follows: (1) ‘ever-exposed’, with all follow-
up time evaluated regardless of treatment discontinuation;
(2) ‘actively on TNFi’, including the follow-up time until
the reported stop date for the TNFi plus 90 days and the
corresponding date for the referents; and (3) ‘short-term
exposure’, defined as actively on a TNFi but with a max-
imum of 2 years of follow-up. Switching from one TNFi
drug to another was considered continuous treatment if
the interval between treatments did not exceed 90 days. In
accordance with the prospective design of our study, if a
previously unexposed biologic-naïve RA patient was
started on treatment with a TNFi, he or she was included
in the TNFi-exposed cohort from that date.
Definition of events and covariates
‘Outcome’ was defined as any first-ever ACS event, which
in turn was defined as a primary discharge diagnosis ofacute myocardial infarction or unstable angina pectoris, or
as acute myocardial infarction being the underlying cause
of death. For discharge diagnoses, the date of admission to
hospital was considered the event date. This outcome def-
inition has previously been validated in a Swedish early
RA cohort, with a positive predictive value of 95% [15].
From the National Patient Register, we extracted in-
and outpatient data since 1987 and 2001, respectively,
on any previous hospitalizations or visits with a main or
contributory diagnosis of chronic obstructive pulmonary
disease, diabetes mellitus, hypertension, cerebrovascular
disease and other atherosclerotic disease, as well as the
number of previous hospital admissions during the
10 years antedating the matching date, any joint surgery
(knee prosthesis, hip prosthesis, shoulder prosthesis, foot
surgery, hand surgery) or hospitalization for infectious
disease prior to inclusion.
‘Duration of RA disease’ was defined as more than
10 years if, at the matching date, the time since the first
entry of an RA diagnosis in the National Patient Register
exceeded 10 years. Data on socioeconomic factors (edu-
cation level, number of days on sick leave and disability
pension in the year before the index date) were retrieved
from the Statistics Sweden database.
For a sensitivity analysis including index patients who
started TNFi on 1 January 2006 or later and their matched
referents, we extracted information on dispensed drugs
during the 6 months before the matching date (acetylsali-
cylic acid, corticosteroids, DMARDs, lipid-lowering
drugs, treatment for hypertension or diabetes, nonste-
roidal anti-inflammatory drugs (NSAIDs) and coxibs) from
the Swedish Prescribed Drug Register.
Statistical methods
Incidence rates for ACS in each cohort were calculated as
the number of observed events divided by the correspond-
ing person-time of follow-up. The relative risks (HRs) for
ACS in patients exposed to a first TNFi were estimated by
Cox proportional hazards regression, in which we com-
pared patients exposed to a first TNFi with the matched
RA referents and with the general population referents,
respectively. In the regression models in which we used
time since start of follow-up as the time scale, we adjusted
for sex, age, county of residence, inclusion year, presence
of any diagnoses indicating previous cardiovascular risk
factors (diabetes mellitus, hypertension and previous cere-
brovascular and/or other atherosclerotic disease), educa-
tion level, sick leave and disability pension during the year
before inclusion, joint surgery, disease duration, previous
infections and chronic pulmonary disease. In sensitivity
analysis restricted to TNFi start and matched comparators
2006 or later, we further adjusted the regression models
for dispensed medications. In these analyses, adjustments
for further cardiovascular risk factors such as treatment
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treatment with corticosteroids, NSAIDs and coxibs, were
possible by extracting from the Swedish Prescribed Drug
Register (in operation since July 2005) information on
dispensed prescribed drugs during the 6-month period
immediately antedating study inclusion.
Analyses were performed using SAS 9.3 software (SAS
Institute, Cary, NC, USA). Survival analyses with Kaplan-
Meier curves were performed using IBM SPSS Statistics for
Windows version 20.0 software (IBM, Armonk, NY, USA).
Results
The clinical and demographic characteristics of the cohorts
at the start of follow-up are given in Table 1. The median
(and mean) follow-up times in the cohort of TNFi-exposed
RA patients were 3.9 (4.2) years for the ‘ever-exposed’ co-
hort, 2.4 (3.1) years for the ‘actively on TNFi’ cohort and
2.0 (1.5) years for the risk window ‘short-term exposure’
cohort. The corresponding figures for the biologic-naïve
cohort were 2.7 (3.3), 2.4 (2.4) and 2.0 (1.5) years, respect-
ively, and for the general population comparator cohort 4.1
(4.3), 2.3 (3.1) and 2.0 (1.7) years, respectively. A majorityTable 1 Clinical and demographic characteristics of study coh
Clinical and demographic characteristics
Female sex
Age, mean ± SD (yr)








Number of days in hospital within 10 years before inclusion, median (IQR)
Previous joint surgeryc
Education level attained
≤9 years or less
10 to 12 years
>12 years
Any disability pension in year before inclusiond
Sick leave the year before inclusione
During part of year (14 to 349 days)
Whole year (≥350 days)
aRA, Rheumatoid arthritis; TNFi, Tumour necrosis factor inhibitor. Values are numbe
includes arterial occlusion and stenosis of cerebral and precerebral arteries, transien
disease, atherosclerosis, aortic aneurysm, other aneurysm or dissection, peripheral a
gangrene. c‘Previous joint surgery’ includes knee prosthesis, hip prosthesis, shoulde
100% of any period of time during the year before inclusion. eThe registered numb
than 5 days. Periods of sick leave lasting 14 days or less are not included in the Staof the TNFi-exposed patients were started on infliximab
(39.5%), etanercept (37.1%) or adalimumab (22.3%) as their
first TNFi, and only a small number of patients received
one of the more recent drugs as their first TNFi (0.8% for
golimumab and 0.4% for certolizumab pegol).
During follow-up (‘ever-exposed’), a total of 221 ACS
events were observed, including 175 (79.2%) primary
diagnoses of myocardial infarction, 25 cases (11.3%) of
unstable angina and 21 (9.5%) events with acute myocar-
dial infarction recorded as the underlying cause of death.
In all risk windows, the crude incidence rates were lower
in the TNFi-exposed cohort compared with the biologic-
naïve RA cohort (Table 2). Kaplan-Meier curves displayed
a higher event-free survival in patients with RA receiving
TNFi treatment compared to the biologic-naïve RA cohort.
The event-free survival rate was lower compared to the
general population comparator for both TNFi-exposed and
biologic-naïve RA patients (Figure 1).
The fully adjusted Cox proportional hazards regression
models resulted in significantly lower risk for ACS among
the TNFi-exposed RA patients compared with the biologic-
naïve RA referents, with an HR of 0.82 for the ever-orts at start of follow-upa
RA patients starting
TNFi (N = 7,704)
Biologic-naïve RA
referents (N = 23,112)
General population
referents (N =38,520)
5,845 (76) 17,535 (76) 29,225 (76)
57.1 ± 12.1 57.3 ± 12.2 57.2 ± 12.2
1,509 (19.6) 3,864 (16.7)
379 (4.9) 1,251 (5.4) 1,342 (3.5)
833 (10.8) 2,689 (11.6) 2,571 (6.7)
196 (2.5) 653 (2.8) 450 (1.2)
177 (2.3) 696 (3.0) 938 (2.4)
505 (6.6) 1,803 (7.8) 1,774 (4.6)
1,675 (21.7) 5,287 (22.9) 5,487 (14.2)
4 (0 to 17) 3 (0 to 14) 0 (0 to 5)
1,974 (25.6) 4,669 (20.2) 1,392 (3.6)
2,197 (28.5) 7,062 (30.6) 10,303 (26.8)
3,494 (45.4) 10,473 (45.3) 16,796 (43.6)
1,983 (25.7) 5,455 (23.6) 11,182 (29.0)
2,601 (33.8) 7,195 (31.1) 4,993 (13.0)
2,091 (27.1) 5,075 (22.0) 4,319 (11.2)
240 (3.1) 596 (2.6) 386 (1.0)
r of patients (%) unless otherwise stated. b‘Other atherosclerotic disease’
t ischaemic attack, cerebral atherosclerosis, late effects of cerebrovascular
rterial disease, arterial embolism or thrombosis, and atherosclerosis with
r prosthesis, foot surgery and hand surgery. d‘Disability pension’ is 25% to
er of days on sick leave also includes work-free days for any sick leave longer
tistics Sweden database.
Table 2 Crude incidence rates for acute coronary syndrome in study cohortsa
TNFi-exposed RA
patients (N = 7,704)
Biologic-naïve RA
patients (N = 23,112)
General population
referents (N = 38,520)
Risk windowb ACS/person-years Crude IR ACS/person-years Crude IR ACS/person-years Crude IR
Ever exposed to TNFi 221/32,621 6.8 (5.9 to 7.7) 680/75,268 9.0 (8.4 to 9.7) 602/165,603 3.6 (3.4 to 3.9)
Actively on TNFi 137/24,055 5.7 (4.8 to 6.7) 476/55,654 8.6 (7.8 to 9.4) 394/118,801 3.3 (3.0 to 3.7)
Short-term exposure 74/11,671 6.3 (5.0 to 8.0) 316/35,204 9.0 (8.0 to 10.0) 216/66,404 3.3 (2.8 to 3.7)
aACS, Acute coronary syndrome; IR, Incidence ratio; RA, Rheumatoid arthritis; TNFi, Tumour necrosis factor inhibitor. ‘Crude IR’ is the incidence per 1,000
person-years expressed as incidence rate (95% confidence interval). b‘Ever exposed’ is all follow-up time after exposure was evaluated, ‘Actively on TNFi’ includes
follow-up time until reported stop date for the TNFi plus 90 days and corresponding date for referents and ‘Short-term exposure’ is defined as actively on TNFi
with follow-up limited to 2 years.
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compared with the general population, the risk for ACS in
both cohorts of RA patients was significantly increased:
The HR (ever-exposed) for the TNFi-exposed patients was
1.61 (95% CI = 1.36 to 1.92), and it was 2.03 (95% CI = 1.80
to 2.29) for the biologic-naïve patients (Table 3). In re-
gression models stratified by sex, age (<65 or ≥65 years),
previous diagnosis of diseases carrying an increased risk


























Start At 2 years follow-up      At 4 years fol
Individuals  Individuals   Cumulative   Individuals   C
at risk at risk ACS (n) at risk A
TNFi 7,704 4,214 74 2,460 1
Bio-naive 23,112 10,044 269 4,988 3
General 
population 34,719 18,825 167 10,931 2
Figure 1 Event-free survival. Kaplan-Meier curves illustrating the proporti
(RA) patients exposed to tumour necrosis factor inhibitors (TNFi) and match
population referents using the risk window ‘actively on TNFi’. ACS, Acute coinclusion (2001 to 2005 or 2006 to 2010), significantly
lower HRs were noted for TNFi-exposed compared to
biologic-naïve RA patients in all subsets (Table 4). Further
sensitivity analyses were performed, including patients
with RA who started TNFi treatment on 1 January 2006
or later (N = 4,285, mean age 56.6 ± 12.7 years, female
sex = 75.9%) and their matched biologic-naïve RA controls
(N = 13,155), including data on medications started within
6 months prior to the matching date. Among the TNFi-Exposure
TNFi exposed RA patients
Bio-naïve RA patients
General population referents
low-up           At 6 years follow-up         At 8 years follow-up  
umulative   Individuals   Cumulative  Individuals  Cumulative
CS (n) at risk ACS (n) at risk ACS (n)
06 1,325 129 407 136
96 2,286 445 527 473
70 5,776 332 1,739 355
on of individuals with event-free survival among rheumatoid arthritis
ed comparator cohorts of biologic-naïve RA patients and general
ronary syndrome.
Table 3 Comparisons of risk for acute coronary syndrome between study cohortsa
Cohort/risk window Biologic-naïve RA comparator General population comparator
HRb (95% CI) HRc (95% CI) HRb (95% CI) HRc (95% CI)
TNFi-treated RA
Ever-exposed 0.81 (0.69 to 0.94) 0.82 (0.70 to 0.95) 1.93 (1.66 to 2.25) 1.61 (1.36 to 1.92)
Actively on TNFi 0.71 (0.58 to 0.86) 0.73 (0.60 to 0.89) 1.73 (1.43 to 2.10) 1.50 (1.21 to 1.85)
Short-term exposure 0.75 (0.58 to 0.97) 0.78 (0.61 to 1.01) 2.07 (1.59 to 2.70) 1.65 (1.23 to 2.22)
Biologic-naïve RA comparator
Ever-exposed – – 2.35 (2.11 to 2.63) 2.03 (1.80 to 2.29)
Actively on TNFi – – 2.41 (2.11 to 2.76) 2.10 (1.82 to 2.43)
Short-term exposure – – 2.63 (2.21 to 3.13) 2.27 (1.89 to 2.73)
aHR, Hazard ratio; RA, Rheumatoid arthritis; TNFi, Tumour necrosis factor inhibitor. bModel adjusted for age, sex and county of residence. cModel stratified for
disability pension during the year before inclusion and adjusted for sex; age at time of inclusion; county of residence; year of inclusion; previous joint surgery;
previous diagnosis of diabetes, hypertension, chronic obstructive pulmonary disease, cerebrovascular disease or other atherosclerotic disease; previous
hospitalization for infectious disease; RA disease duration longer than 10 years (biologic-naïve and TNFi comparison); total number of days in hospital during
10 years prior to inclusion; sick leave; and education level.
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with a DMARD and/or oral corticosteroid within 6 months
before inclusion in the study, and, in the biologic-naïve
cohort, the corresponding figure was 78.5% (N = 10,329).
The baseline characteristics of the patients included in the
sensitivity analysis are presented in Additional file 2. The
results of these further adjustments are not markedly dif-
ferent from those of the main analysis, although the HRs
in this smaller sample were statistically significant only for
the risk window ‘actively on TNFi’ (Table 5).
Discussion
In our nationwide, population-based cohort study, we
observed a lower risk of incident ACS in patients with
RA starting a first TNFi compared to patients with RA
treated otherwise. However, the risk for a first-time ACS
event among patients with RA, whether treated with











Female 143/24,978 420/57,583 0.85
Male 78/7,643 260/17,682 0.74
Age <65 yr 111/25,208 331/55,041 0.76
Age ≥65 yr 110/7,413 349/20,227 0.87
Cardiovascular risk factor present 70/5,520 259/15,321 0.78
No previous cardiovascular risk factor 151/27,101 421/59,946 0.86
TNFi start 2001 to 2005 175/22,505 517/48,870 0.81
TNFi start 2006 to 2010 46/10,116 163/26,398 0.77
aACS, Acute coronary syndrome; RA, Rheumatoid arthritis; TNF, Tumour necrosis fac
analysis stratified for sex was adjusted for age and county of residence. ‘Cardiovasc
cerebrovascular and/or other atherosclerotic disease.the general population. The association between TNFi
treatment and risk of ACS was the most pronounced for
patients being treated with ongoing TNFi therapy, but
the point estimates were in the same order of magnitude
in all of the subpopulations assessed, whether stratified
by sex, age, previous occurrence of diagnoses reflecting
cardiovascular risk factors or year of TNFi therapy start.
In several studies during recent years, researchers have
evaluated the risk for ischaemic heart disease, myocardial
infarction or ACS after TNFi therapy, with inconsistent
results [12,14,15,17-21]. In our previous publication with
our colleagues in the Swedish ARTIS Study Group [15],
no statistically significant difference in risk for ACS was
seen in early RA, without regard to TNFi exposure, but
we did find a point estimate (HR = 0.80, 95% CI = 0.52 to
1.24) in keeping with that calculated in our present study.
Two earlier observational studies have shown a decreased














(0.70 to 1.03) 79/18,170 282/42188 0.70 (0.54 to 0.90)
(0.57 to 0.96) 58/5,885 194/13466 0.72 (0.53 to 0.96)
(0.61 to 0.94) 74/18,969 250/42089 0.68 (0.52 to 0.89)
(0.70 to 1.07) 63/5,086 226/13,565 0.75 (0.57 to 0.99)
(0.60 to 1.02) 43/3,898 185/11,154 0.67 (0.48 to 0.93)
(0.71 to 1.04) 94/20,157 291/44,500 0.77 (0.61 to 0.97)
(0.68 to 0.97) 106/15,627 344/33,726 0.72 (0.58 to 0.90)
(0.55 to 1.07) 31/8,427 132/21,928 0.64 (0.43 to 0.95)
tor. bThe analyses were adjusted for age, sex and county of residence. The
ular risk factor’ refers to any previous diagnosis of diabetes, hypertension and
Table 5 Sensitivity analyses adjusted for pharmacological treatment in rheumatoid arthritis patients included 1 January 2006 and latera






















HRb (95% CI) HRc (95% CI)
Ever exposed to TNFi 46/10,116 163/26,398 162/50,692 0.77 (0.55 to 1.07) 0.72 (0.51 to 1.02) 1.45 (1.05 to 2.02) 1.83 (1.47 to 2.27)
Actively on TNFi 31/8,427 132/21,928 128/41,757 0.64 (0.43 to 0.95) 0.64 (0.43 to 0.96) 1.21 (0.82 to 1.79) 1.85 (1.45 to 2.36)
Short-term exposure 22/5,986 107/18,229 102/33,574 0.69 (0.44 to 1.09) 0.64 (0.40 to 1.03) 1.27 (0.80 to 2.02) 1.83 (1.39 to 2.40)
aACS, Acute coronary syndrome; HR, Hazard ratio; RA, Rheumatoid arthritis; TNFi, Tumour necrosis factor inhibitor. bAdjusted for age, sex and county of residence. cAdjusted for sex; age; county of residence; year of
inclusion; diabetes mellitus (treatment and/or previous diagnosis); hypertension (treatment and/or previous diagnosis); previous diagnosis of chronic obstructive pulmonary disease, cerebrovascular disease or other
atherosclerotic disease; previous hospitalization for infection; total number of days in hospital during 10 years prior to inclusion; RA disease duration more than 10 years; sick leave; disability pension; previous joint
surgery; education level; and dispensed pharmacological treatment within 6 months prior to inclusion (acetylsalicylic acid, corticosteroids, disease-modifying antirheumatic drugs, lipid-lowering drugs, nonsteroidal















Ljung et al. Arthritis Research & Therapy 2014, 16:R127 Page 8 of 10
http://arthritis-research.com/content/16/3/R127treatment compared to patients treated otherwise, with
relative risks of 0.24 (95% CI = 0.06 to 0.95) [14] and 0.42
(95% CI = 0.21 to 0.81) [16]. Researchers in another study,
with the outcome of ischaemic heart disease, reported a
lower risk among TNFi-exposed patients (relative risk =
0.18 (95% CI = 0.05 to 0.61)) [12]. In a meta-analysis pub-
lished in 2011 that included two of the studies cited above
[13,16], two earlier Swedish studies [27,28] and abstract
data from another two studies [29,30], the authors pre-
sented a pooled relative risk of 0.81 (95% CI = 0.68 to
0.96) for myocardial infarction associated with TNFi treat-
ment [31]. To the best of our knowledge, no studies so far
have shown any increase in the risk of coronary events
after TNFi exposure. Despite the fact that we included pa-
tients from recent years, since 2001, after the introduction
of TNFi and during a time span with remission or low dis-
ease activity as a goal for RA therapy, the risk for ACS
among the RA patients compared to that in the general
population was markedly increased. This indicates a
remaining gap in risk for ischaemic heart disease between
patients with RA and the general population during the
calendar period in our study.
The strengths of this study include its large and na-
tionwide setting and its comparatively large number of
subjects and events. The high coverage of the Swedish
Biologics Register [25] assured a low risk of misclassifi-
cation of TNFi exposure. Furthermore, the register link-
age allowed for adjustments regarding several possible
confounders: cardiovascular risk factors, such as diag-
nosed hypertension, diabetes mellitus and prevalent ath-
erosclerotic disease, as well as socioeconomic predictors
of cardiovascular risk, such as education level, sick leave
and disability pension. Information on prescribed medi-
cation was available in a subset of patients, allowing
further adjustments for lipid-lowering, antidiabetic and
antihypertensive therapy, DMARD therapy and treatment
with drugs that might increase the risk of ACS (for ex-
ample, corticosteroids, NSAIDs and coxibs). Access to
data on general population referents provided us with the
ability to contextualize the findings within the RA cohorts.
The study also has a number of limitations that should
be acknowledged, however. We used the Swedish Patient
Register to identify patients with RA. For the majority of
individuals, therefore, specific RA-related data were not
available. The frequency of joint surgery, DMARD and
corticosteroid use (see Additional file 2), long RA disease
duration and work-related disability in the RA cohorts
(Table 1) indicate that the patients in the TNFi-exposed
RA cohort were likely to have more severe or insufficiently
controlled RA disease. It is unclear whether these adjust-
ments were fully sufficient to adjust for disease activity,
and therefore there might be remaining confounders (and
confounding by indication, that is, that the start of TNFi
treatment is per se an indicator of more severe RAdisease). If RA activity were associated with the risk of
ACS (and if other risk factors were comparable between
the cohorts), a higher baseline risk level would be antici-
pated among the TNFi-exposed individuals. If so, this
would have attenuated rather than inflated our findings.
Regarding traditional cardiovascular risk factors, we had
information on diagnoses of hypertension and diabetes
mellitus and, in the sensitivity analyses, treatment for
these risk factors and for hyperlipidaemia, but we had no
information regarding smoking habits, blood pressure,
glucose levels or anthropometric measurements. The fre-
quency of risk factors (diagnosis of or treatment for) be-
tween the cohorts was similar, however.Conclusions
We found that patients with RA started on TNFi therapy
in clinical practice had a lower risk of risk of ACS com-
pared to RA patients treated otherwise. Compared with the
general population, however, the risk for ACS in RA pa-
tients, regardless of TNFi treatment, was still increased.
Further measures are thus needed to prevent premature
coronary events in patients with RA, most likely by includ-
ing disease control as well as other risk factor interventions.Additional files
Additional file 1: List of International Classification of Diseases
(ICD) codes used for identification of the diagnoses covered in
the study.
Additional file 2: Baseline characteristics of TNFi-exposed patients
who started TNFi on 1 January 2006 or later and their matched
biologic-naïve comparators.Abbreviations
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arthritis; TNFi: Tumour necrosis factor inhibitor.
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